Systemic toll-like receptor ligation and selective killing of dendritic cell subsets fail to dissect priming pathways for anti-vaccinia virus CD8+ T cells

Journal of Virology

Volumn 87, Issue 22, 2013, Pages 11978-11986

  Wong, Yik Chun ^a   Smith, Stewart A ^a   Tscharke, David C ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CYTOCHROME C; EPITOPE; TOLL LIKE RECEPTOR; VACCINIA VACCINE; VIRUS ANTIGEN; CPG-OLIGONUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL EXPERIMENT; ANTIGEN FUNCTION; ARTICLE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL KILLING; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; DRUG DOSE COMPARISON; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; ANTIGEN PRESENTATION; C57BL MOUSE; DRUG EFFECTS; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; SKIN; VACCINIA; VIROLOGY;

MUS; VACCINIA VIRUS;

ANIMALS; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; CYTOCHROMES C; DENDRITIC CELLS; FEMALE; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; SKIN; TOLL-LIKE RECEPTORS; VACCINIA; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 84886306982     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01835-13     Document Type: Article

References (48)

1. Rotzschke O, Falk K, Deres K, Schild H, Norda M, Metzger J, Jung G, Rammensee H-G. 1990. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348:252-254.
2. Bevan MJ. 1976. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143:1283-1288.
3. Heath WR, Carbone FR. 2009. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat. Immunol. 10:1237-1244.
4. Gainey MD, Rivenbark JG, Cho H, Yang L, Yokoyama WM. 2012. Viral MHC class I inhibition evades CD8+ T-cell effector responses in vivo but not CD8+ T-cell priming. Proc. Natl. Acad. Sci. U. S. A. 109:E3260-E3267. doi:10.1073/pnas.1217111109.
5. Holtappels R, Podlech J, Pahl-Seibert M-F, Julch M, Thomas D, Simon CO, Wagner M, Reddehase MJ. 2004. Cytomegalovirus misleads its host by priming of CD8 T cells specific for an epitope not presented in infected tissues. J. Exp. Med. 199:131-136.
6. Norbury CC, Sigal LJ. 2003. Cross priming or direct priming: is that really the question? Curr. Opin. Immunol. 15:82-88.
7. + T cell cross-priming via transfer of proteasome substrates. Science 304:1318-1321.
8. Wolkers MC, Brouwenstijn N, Bakker AH, Toebes M, Schumacher TNM. 2004. Antigen bias in T cell cross-priming. Science 304:1314-1317.
9. Restifo NP, Bacik I, Irvine KR, Yewdell JW, McCabe BJ, Anderson RW, Eisenlohr LC, Rosenberg SA, Bennink JR. 1995. Antigen processing in vivo and the elicitation of primary CTL responses. J. Immunol. 154:4414-4422.
10. + T cell response. PLoS Pathog. 6:e1000768. doi:10.1371/journal.ppat.1000768.
11. + T cells in the peripheral interfollicular region of lymph nodes. Nat. Immunol. 9:155-165.
12. Wilson NS, Behrens GMN, Lundie RJ, Smith CM, Waithman J, Young L, Forehan SP, Mount A, Steptoe RJ, Shortman KD, de Koning-Ward TF, Belz GT, Carbone FR, Crabb BS, Heath WR, Villadangos JA. 2006. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol. 7:165-172.
13. Gasteiger G, Kastenmuller W, Ljapoci R, Sutter G, Drexler I. 2007. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J. Virol. 81:11925-11936.
14. + T cell responses in the lymph node. Immunity 38:502-513.
15. + dendritic cells by cytochrome c injection shows functional heterogeneity within this subset. Proc. Natl. Acad. Sci. U. S. A. 105:3029-3034.
16. + dendritic cells are critical for crosspriming and IL-12 production in response to systemic antigens. J. Immunol. 183:7732-7742.
17. + T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes. Nat. Med. 13:1035-1041.
18. Imai T, Kato Y, Kajiwara C, Mizukami S, Ishige I, Ichiyanagi T, Hikida M, Wang J-Y, Udono H. 2011. Heat shock protein 90 (HSP90) contributes to cytosolic translocation of extracellular antigen for crosspresentation by dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 108:16363-16368.
19. Cockburn IA, Tse S-W, Radtke AJ, Srinivasan P, Chen Y-C, Sinnis P, Zavala F. 2011. Dendritic cells and hepatocytes use distinct pathways to process protective antigen from Plasmodium in vivo. PLoS Pathog. 7:e1001318. doi:10.1371/journal.ppat.1001318.
20. Sutherland RM, Zhan Y, Carrington EM, Londrigan SL, Lew AM. 2011. Selective depletion of cross-presenting dendritic cells enhances islet allograft survival. Cell Transplant. 20:467-474.
21. Wong YC, Lin LCW, Melo-Silva CR, Smith SA, Tscharke DC. 2011. Engineering recombinant poxviruses using a compact GFP-blasticidin resistance fusion gene for selection. J. Virol. Methods 171:295-298.
22. Chakrabarti S, Brechling K, Moss B. 1985. Vaccinia virus expression vector: coexpression of β-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5:3403-3409.
23. Lin LCW, Smith SA, Tscharke DC. 2012. An intradermal model for vaccinia virus pathogenesis in mice. Methods Mol. Biol. 890:147-159.
24. + T cells. PLoS One 7:e39533. doi:10.1371/journal.pone.0039533.
25. Tscharke DC, Smith GL. 1999. A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae. J. Gen. Virol. 80:2751-2755.
26. + T cells by infected dendritic cells in vivo. Nat. Immunol. 3:265-271.
27. + CTL following exposure to vaccinia virus via different routes. J. Immunol. 169:4222-4229.
28. Serna A, Ramirez MC, Soukhanova A, Sigal LJ. 2003. Cutting edge: efficient MHC class I cross-presentation during early vaccinia infection requires the transfer of proteasomal intermediates between antigen donor and presenting cells J. Immunol. 171:5668-5672.
29. Antoine G, Scheiflinger F, Dorner F, Falkner FG. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396.
30. Wyatt LS, Earl PL, Eller LA, Moss B. 2004. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl. Acad. Sci. U. S. A. 101: 4590-4595.
31. Stittelaar KJ, van Amerongen G, Kondova I, Kuiken T, van Lavieren RF, Pistoor FHM, Niesters HGM, van Doornum G, van der Zeijst BAM, Mateo L, Chaplin PJ, Osterhaus ADME. 2005. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J. Virol. 79:7845-7851.
32. Tsung K, Yim JH, Marti W, Buller RM, Norton JA. 1996. Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light. J. Virol. 70:165-171.
33. + T-cell priming. J. Gen. Virol. 88:2378-2386.
34. Lin LCW, Flesch IEA, Tscharke DC. 25 April 2013. Immunodomination during peripheral vaccinia virus infection. PLoS Pathog. 9(4):e1003329. doi:10.1371/journal.ppat.1003329.
35. Rees DGC, Gates AJ, Green M, Eastaugh L, Lukaszewski RA, Griffin KF, Krieg AM, Titball RW. 2005. CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. Antiviral Res. 65:87-95.
36. + T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host. J. Immunol. 177:6336-6343.
37. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, Zinkernagel R, Aguzzi A. 2004. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10:187-192.
38. Baban B, Chandler PR, Johnson BA, Huang L, Li M, Sharpe ML, Francisco LM, Sharpe AH, Blazar BR, Munn DH, Mellor AL. 2011. Physiologic control of IDO competence in splenic dendritic cells. J. Immunol. 187:2329-2335.
39. Wingender G, Garbi N, Schumak B, Jüngerkes F, Endl E, von BubnoffD, Steitz J, Striegler J, Moldenhauer G, Tüting T, Heit A, Huster KM, Takikawa O, Akira S, Busch DH, Wagner H, Hämmerling GJ, Knolle PA, Limmer A. 2006. Systemic application of CpGrich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 36:12-20.
40. + T cell immunodominance in lymphocytic choriomeningitis virus infection is modified in the presence of Tolllike receptor agonists. J. Virol. 85:13224-13233.
41. Croft NP, Smith SA, Wong YC, Tan CT, Dudek NL, Flesch IEA, Lin LCW, Tscharke DC, Purcell AW. 2013. Kinetics of antigen expression and epitope presentation during virus infection. PLoS Pathog. 9:e1003129. doi:10.1371/journal.ppat.1003129.
42. Princiotta MF, Finzi D, Qian SB, Gibbs J, Schuchmann S, Buttgereit F, Bennink JR, Yewdell JW. 2003. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18:343-354.
43. + T cell immunodominance after vaccinia virus infection and the naïve repertoire in inbred and F1 mice. J. Immunol. 184:45-55.
44. Chow A, Toomre D, Garrett W, Mellman I. 2002. Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane. Nature 418:988-994.
45. Bouvier I, Jusforgues-Saklani H, Lim A, Lemaître F, Lemercier B, Auriau C, Nicola M-A, Leroy S, Law HK, Bandeira A, Moon JJ, Bousso P, Albert M. 2011. Immunization route dictates cross-priming efficiency and impacts the optimal timing of adjuvant delivery. Front. Immunol. 2:71.
46. + dendritic cells are generally involved in priming CTL immunity to viruses. J. Immunol. 172: 1996-2000.
47. + dendritic cells in cytotoxic t cell immunity. Science 322:1097-1100.
48. Iborra S, Izquierdo HM, Martinez-Lopez M, Blanco-Menendez N, Creis e Sousa Sancho D. 2012. The DC receptor DNGR-1 mediates crosspriming of CTLs during vaccinia virus infection in mice. J. Clin. Invest. 122:1628-1643.